Precision BioSciences Unveils Positive Phase 1 ELIMINATE-B Trial Results for PBGENE-HBV
Precision BioSciences Inc. announced positive Phase 1 ELIMINATE-B trial results for PBGENE-HBV, a gene editing therapy for chronic hepatitis B. The data will be presented at the Hep-DART 2025 conference on December 9, 2025, covering safety and antiviral activity across three cohorts. The study aims to evaluate PBGENE-HBV's potential to eliminate and inactivate viral templates responsible for hepatitis B infection.
Precision BioSciences Inc. announced that new clinical data from its Phase 1 ELIMINATE-B trial of PBGENE-HBV, a first-in-class gene editing therapy for chronic hepatitis B, will be presented at the Hep-DART 2025 conference. The oral presentation is scheduled for December 9, 2025, and will cover safety and antiviral activity data across three cohorts. The study is designed to evaluate the potential of PBGENE-HBV to directly eliminate and inactivate viral templates responsible for ongoing hepatitis B infection. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251119821874) on November 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
